Development of Pharmaceutical Equivalent Montelukast Sodium Immediate-Release, Film-Coated Tablets

Q2 Pharmacology, Toxicology and Pharmaceutics
Poowadon Muenraya, Apichart Atipairin, T. Srichana, N. Changsan, Neelam Balekar, Somchai Sawatdee
{"title":"Development of Pharmaceutical Equivalent Montelukast Sodium Immediate-Release, Film-Coated Tablets","authors":"Poowadon Muenraya, Apichart Atipairin, T. Srichana, N. Changsan, Neelam Balekar, Somchai Sawatdee","doi":"10.26554/sti.2024.9.1.43-58","DOIUrl":null,"url":null,"abstract":"Montelukast tablets are sold under the brand name Singulair and are used to control and prevent asthma symptoms. In this study, 10 mg film-coated montelukast tablets were developed as a generic drug in order to evaluate the pharmaceutical equivalent of the innovator’s products. The primary formulation ingredients used in all developed formulations (F1-F5) were the same as those described in the Singulair tablet package insert, except for formulations F3, F4, and F5, to which solubilizing enhancers were added to increase montelukast solubility. The core tablets were produced using the wet granulation method before being coated with HPMC polymer. FT-IR and DSC were used to determine drug and excipient compatibility. The micromeritic properties of the granules were assessed. The physicochemical properties of generated montelukast tablets and Singulair tablets were also investigated. The dissolution profiles of the tested drug and the innovator were assessed in a variety of pH mediums (pH 1.2, 4.5, 6.8, and water). The similarity (f2) and difference (f1) factors were computed. The accelerated and long-term stability of the tested drug in hot and humid climate zones was evaluated. The analytical method validation used in this study was ICH-acceptable for 8 parameters including specificity, range, linearity, accuracy, precision, limit of detection, limit of quantitation, and robustness. F1-F5 granules had similar properties, such as a pale-yellow color and excellent flow properties. There were no chemical interactions between montelukast and the excipients according to FT-IR and DSC analyses. The physical properties of all developed montelukast film-coated tablets were similar (average weight 212-218 mg; thickness 3.02-3.07 mm; assay 101-102% LA; disintegration time 3-4 min), except that the disintegration time of F3 was 8.10 min and that of F5 was 5.90 min, which was caused by the addition of poloxamer 188 to the formulation. In all mediums, only the F1 formula produced acceptable comparison dissolution profiles to Singulair. After 6 months of storage under accelerated and long-term conditions, the results showed the F1 formulation remained physically and chemically stable.","PeriodicalId":21644,"journal":{"name":"Science and Technology Indonesia","volume":"17 9","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Science and Technology Indonesia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26554/sti.2024.9.1.43-58","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

Abstract

Montelukast tablets are sold under the brand name Singulair and are used to control and prevent asthma symptoms. In this study, 10 mg film-coated montelukast tablets were developed as a generic drug in order to evaluate the pharmaceutical equivalent of the innovator’s products. The primary formulation ingredients used in all developed formulations (F1-F5) were the same as those described in the Singulair tablet package insert, except for formulations F3, F4, and F5, to which solubilizing enhancers were added to increase montelukast solubility. The core tablets were produced using the wet granulation method before being coated with HPMC polymer. FT-IR and DSC were used to determine drug and excipient compatibility. The micromeritic properties of the granules were assessed. The physicochemical properties of generated montelukast tablets and Singulair tablets were also investigated. The dissolution profiles of the tested drug and the innovator were assessed in a variety of pH mediums (pH 1.2, 4.5, 6.8, and water). The similarity (f2) and difference (f1) factors were computed. The accelerated and long-term stability of the tested drug in hot and humid climate zones was evaluated. The analytical method validation used in this study was ICH-acceptable for 8 parameters including specificity, range, linearity, accuracy, precision, limit of detection, limit of quantitation, and robustness. F1-F5 granules had similar properties, such as a pale-yellow color and excellent flow properties. There were no chemical interactions between montelukast and the excipients according to FT-IR and DSC analyses. The physical properties of all developed montelukast film-coated tablets were similar (average weight 212-218 mg; thickness 3.02-3.07 mm; assay 101-102% LA; disintegration time 3-4 min), except that the disintegration time of F3 was 8.10 min and that of F5 was 5.90 min, which was caused by the addition of poloxamer 188 to the formulation. In all mediums, only the F1 formula produced acceptable comparison dissolution profiles to Singulair. After 6 months of storage under accelerated and long-term conditions, the results showed the F1 formulation remained physically and chemically stable.
开发药效相当的孟鲁司特钠速释薄膜衣片
孟鲁司特片以 Singulair 品牌销售,用于控制和预防哮喘症状。本研究将 10 毫克蒙脱司特薄膜衣片作为仿制药进行开发,以评估创新药产品的药效等同性。所有开发的制剂(F1-F5)中使用的主要配方成分与辛格列奈片剂包装说明书中描述的成分相同,但制剂 F3、F4 和 F5 除外,其他制剂均添加了增溶促进剂,以增加孟鲁司特的溶解度。片芯采用湿法制粒法生产,然后涂上 HPMC 聚合物。利用傅立叶变换红外光谱和 DSC 测定药物与辅料的相容性。对颗粒的微粒特性进行了评估。还对生成的孟鲁司特片和辛格列奈片的理化性质进行了研究。在各种 pH 介质(pH 值为 1.2、4.5、6.8 和水)中评估了受试药物和创新药的溶出曲线。计算了相似系数(f2)和差异系数(f1)。评估了被测药物在湿热气候区的加速稳定性和长期稳定性。本研究采用的分析方法在特异性、范围、线性、准确性、精密度、检出限、定量限和稳健性等 8 个参数上均符合 ICH 标准。F1-F5 颗粒具有相似的特性,如淡黄色和优异的流动性。根据 FT-IR 和 DSC 分析,孟鲁司特与辅料之间没有化学作用。除 F3 的崩解时间为 8.10 分钟和 F5 的崩解时间为 5.90 分钟外,所有已研制出的孟鲁司特薄膜衣片的物理性质均相似(平均重量为 212-218 毫克;厚度为 3.02-3.07 毫米;测定值为 101-102% LA;崩解时间为 3-4 分钟),这是因为配方中添加了 poloxamer 188。在所有介质中,只有 F1 配方与辛格列奈的比较溶解度曲线是可接受的。在加速和长期条件下贮存 6 个月后,结果显示 F1 配方仍然保持物理和化学稳定性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Science and Technology Indonesia
Science and Technology Indonesia Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
CiteScore
1.80
自引率
0.00%
发文量
72
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信